💥 Market's HUGE Bet Just Fell Flat
Plus: Biotech’s New Crown Jewel?, and More
Hey,
We wanted to loop you into something awesome we've been digging lately: Money Machine Newsletter.
This isn't your usual finance fluff—it's crafted specifically for ambitious investors who want the inside track without sifting through hours of noise.
Here's what makes it standout:
Market-Beating Stock Picks: Handpicked by elite traders, distilled into a 5-minute weekly read, delivered straight to your inbox—before the market opens.
Insider-Level Insights: Fresh perspectives on markets, investing, and business directly from seasoned insiders and industry experts—not the same recycled stories from mainstream media.
Forget the watered-down picks. Forget the mainstream noise. This is real investing intel designed to level up your game, fast.
I’ll let Money Machine Newsletter take it from here…
This week’s market, investing, and business insights from insiders and experts outside the mainstream media:
Market's BIG bet just fell flat.
THIS Biotech thinks it cracked a multi-billion dollar problem.
IPOs might be back—these names are making moves.
Investors feel the heat with THIS correction.
And more. Let’s get to it!
Top Insights of the Week
1. 💥 Market's HUGE Bet Just Fell Flat
For decades, politicians measured success by how high the stock market climbed. Now? Trump 2.0 might flip the script…
Shifting focus from Wall Street to Main Street… this could mean a major shake-up for investors, businesses, and global markets.
Instead… policies could focus on small businesses, manufacturing, and middle-class jobs over stock market gains.
That’s a MAJOR switch-up… last time around, he tied his presidency to the markets. This time? Not so much.
Why crash stocks on purpose?… sounds crazy, right? not really…
High stock prices fuel inflation… when markets soar, investors cash out, buy second homes, new cars, and luxury goods. That drives up prices for everyone.
Drop stocks, cool inflation… if equity markets deflate, people spend less, which naturally slows inflation without the Fed needing to raise rates.
When stocks tumble, investors run to bonds… that pushes bond yields down. And that’s a big deal because the U.S. has $1 trillion in debt to refinance…
Lower bond yields = cheaper borrowing for the government.
Cheaper borrowing = less pressure on taxpayers.
If Trump sticks to this new plan, expect volatility. Markets hate change, and this is a big one. But if rates drop and inflation cools? Main Street could finally catch a break. So, who wins and who loses?…
Who wins…
Small businesses… lower interest rates could make it easier to borrow.
Manufacturing… bringing jobs back home could be a real push.
Who loses?
Stock market investors… if policies don’t favor Wall Street, expect some pain.
Wealthy asset holders… with stocks down, high-end spending on real estate, luxury goods, and services could slow.
2. 💉 Biotech’s New Crown Jewel?
Regenerative medicine is completely re-thinking healthcare, treating disease at the cellular level. But it’s costly and slow… one company thinks it cracked a solution… Orgenesis…
Orgenesis built the POCare Platform—hospitals can make therapies onsite, skipping costly logistics. Think Henry Ford’s assembly line, but for personalized medicine.
Here’s why we’re paying close attention…
Regenerative medicine is a $399B market. If Orgenesis' tech takes off, they could be a major player.
Strong pipeline of patents, 17… plus 30+ therapies in development, including nanotech for cancer detection and cell therapies for heart repair.
Strong partnerships with major institutions like Johns Hopkins.
They bought Neurocords' tech to turn stem cells into spinal cord neurons. The goal? Make treatments cheaper and easier. The market’s set to grow from $7.5B to $11.2B by 2031.
Pitfalls…
Regulatory hurdles… trials and approvals are slow and uncertain.
Orgenesis has a unique decentralized model, but big players like Vertex and upstarts like NanoXplore raise the stakes. They need to execute flawlessly.
Higher volatility… price swings can be extreme due to low trading volume.
Bottom line…
Orgenesis is a bold bet on regenerative medicine. High risk, high reward. If they pull it off, the upside could be huge.
This is where Money Machine Newsletter comes in. We spot momentum, lock in gains, and cuts risk with our exclusive setups. Become a premium subscriber and get alerted when this stock triggers our setup for entry point, target price, and stop loss.
3. 🥩 Investors Demand Meat, Not Sizzle
After a long freeze, IPOs could be making a comeback…
Figma got blocked from selling to Adobe, so now an IPO is on the table.
Discord is dropping hints about a liquidity event.
Crypto firms like Kraken and Gemini see an opening after the crypto market’s rebound.
But the market isn’t just throwing money at anything anymore… investors aren’t interested in flashy, unprofitable startups… the real winners this time will be companies that can prove they’re sustainable…
Figma is a category leader with deep enterprise adoption.
Discord? Still figuring out its business model. Tougher sell.
Crypto IPOs? The Wild West. Regulatory wins help, but trust issues remain.
If these IPOs succeed, it signals that Wall Street is ready to bet on tech again—but under new rules…
Profitable, durable companies? In.
Hype-driven, cash-burning startups? Out.
The IPO market isn’t just reopening—it’s resetting.
Top 3 Charts of the Week
1. 🩸 The Nasdaq Hits Correction Territory
The Nasdaq, packed with tech stocks, is down 10% since December—that’s a correction. It’s not the dot-com crash, but investors feel the heat.
The difference from the dot-com era? Many firms today make real money—Broadcom pulled in $5.5B last quarter. But if the slide continues, pricey tech stocks could still take a hit.
2. 🥗 Why Selling $16 Salads Isn’t Working
Sweetgreen, famous for pricey salads, is adding fries to the menu. They hope it helps turn a profit since they lost $90M in 2024, or about $2.26 per salad sold.
Despite $677M in revenue, high costs are crushing profits. Fries are cheap and popular, but investors aren’t buying it—Sweetgreen’s stock is down 34% since February.
3. 🚘 Tesla’s Grip on Used EV Market Weakens
Tesla’s used car prices have crashed—down 58% from $71K in 2022 to $30K today. Even with discounts, demand is fading, and rivals are catching up.
Its grip on the EV market is slipping. New car sales are slowing, driverless tech is lagging, and even used Teslas aren’t moving like before.
Join 6,000+ self-directed investors who have already placed themselves on the path to greater wealth by making $500, $1,000, $2,000, $3,000, or more every month with Money Machine Newsletter’s trade ideas.
See you in there!
Best,
Money Machine Newsletter
 | A guest post by
|